A5093729161- COVID-19 and healthcare impacts
- COVID-19 Clinical Research Studies
- Neutropenia and Cancer Infections
- Inflammatory Biomarkers in Disease Prognosis
- Acute Myeloid Leukemia Research
- Cancer Immunotherapy and Biomarkers
- SARS-CoV-2 and COVID-19 Research
- Lymphoma Diagnosis and Treatment
- Long-Term Effects of COVID-19
City Clinical Hospital
2024
Background . At the end of 2019, a new coronavirus infection caused by SARS-CoV-2 virus was registered. In March 2020, first cases COVID-19 were detected in Moscow. Patients with chronic lymphocytic leukemia, characterized profound immune dysfunction, have risk factors for severe viral disease. Aim To identify hospital mortality and course COVID-19, as well to optimize therapeutic preventive measures. Materials methods The analysis included 238 patients (142 (59 %) men 96 (41 women) leukemia...
Background . Acute myeloid leukemia (AML) is a highly aggressive oncological disease of the blood and bone marrow, requiring extremely toxic chemotherapy massive supportive treatment to achieve stable remission. Currently, there no work provide medical care these patients with high risk coronavirus infection. This paper presents results large AML patient cohort during COVID-19 pandemic. Aim To assess clinical features infection in patients. Materials methods A retrospective study included...
In December 2019, cases of severe respiratory infection were reported in Wuhan, China. The disease was caused by a new, previously undescribed coronavirus, structurally similar to the then known SARS-CoV virus. World Health Organization has named new virus SARS-CoV-2 and it causes COVID-19. problem COVID-19 is exacerbated rapid spread development life-threatening complications, main which pneumonia. Due severity condition, from 5 10 % patients are treated intensive care units. initially...
Aim . To study the course of COVID-19 (COronaVIrus Disease 2019) in elderly patients with acute myeloid leukemia (AML), to analyze risk factors for unfavorable outcome. Materials and methods The paper presents our own experience treatment (age ≥65 years) AML concomitant coronavirus infection hematology departments City Clinical Hospital No. 52 (Moscow) from March 2020 June 2022. diagnosis was considered confirmed based on a positive result polymerase chain reaction an oropharyngeal...
Background . Coronavirus disease (COVID-19), caused by SARS-CoV-2, presents new challenges to hematologists, highlighting the vulnerability of patients with hematological malignancies, in particular diffuse large B-cell lymphoma (DLBCL). Identification hospital mortality risk factors is necessary for subsequent stratification into groups, which will allow further risk-based therapy. Aim To develop a prognostic model and identify DLBCL associated COVID-19. Materials methods The interim...